Trial
NCT07000630
Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis
UnknownTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Peking University First Hospital
Collaborators
—
Condition
Palmoplantar Pustulosis
Intervention
Deucravacitinib
Why stopped
Terminated early due to lack of expected efficacy. Three participants were enrolled but none completed the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-11